Tivozanib(Fotivda)

Tivozanib is a prescription drug targeting vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3. It was approved for marketing by the European Commission on August 24, 2017, and by the U.S. Food and Drug Administration (FDA) on March 10, 2021. It should be used strictly under medical supervision.

Targets

(VEGFR)-1, VEGFR-2 and VEGFR-3

Dosage and Administration

Route and frequency of Tivozanib administration: Oral, once daily.

The dosage of Tivozanib should be adjusted according to the patient's actual condition. Please consult your doctor and follow the prescription.

Recommended reading: Dosage and Administration of Tivozanib

Side Effects

Common side effects: Fatigue, diarrhea, decreased appetite, etc.

Serious side effects: Hypertension, heart failure, bleeding problems, etc.

Reference article: Side Effects of Tivozanib

Use in Special Populations

Pregnancy: Inform your healthcare provider if you are pregnant or plan to become pregnant. Tivozanib may cause harm to an unborn baby.

Breastfeeding: Do not breastfeed during treatment with Tivozanib and for 1 month after the last dose.

Daily Precautions

1. Inform patients that hypertension or hypertensive crisis may occur during Tivozanib treatment. Instruct patients to monitor blood pressure regularly and contact their healthcare provider if blood pressure rises; if symptoms or signs of hypertension occur, contact their healthcare provider immediately.

2. Inform patients that arterial thromboembolic events (including fatal outcomes) may occur during Tivozanib treatment. If patients experience new chest discomfort, sudden limb weakness, or other symptoms suggestive of a thrombotic event, contact their healthcare provider immediately.

3. Instruct patients to contact their healthcare provider and seek immediate medical attention if they experience abnormal bleeding or symptoms and signs related to bleeding.

from FDA，2021.03